Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nitrofurazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.87 |
| ▸ | TP53 | P04637 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.87 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.87 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.87 |
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | MITF | O75030 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrofurazone SCHEMBL25417 | 0.93 | LMNA (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL3681048 | 0.93 | LMNA (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL25416 | 0.93 | LMNA (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL28198181 | 0.92 | LMNA (0.97) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL28285714 | 0.91 | LMNA (0.94) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL20775188 | 0.90 | LMNA (0.87) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL28246849 | 0.88 | LMNA (0.83) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nitrofurazone SCHEMBL28871281 | 0.86 | LMNA (0.81) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nihydrazone SCHEMBL525528 | 0.85 | HTT (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E | |
| Nihydrazone SCHEMBL525529 | 0.85 | HTT (1.00) | LMNAALDH1A1CYP3A4CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8679518-B2 | Antimicrobial compounds having protective or therapeutic leaving groups | MEDTRONIC, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120157373-A1 | ANTIMICROBIAL COMPOUNDS HAVING PROTECTIVE OR THERAPEUTIC LEAVING GROUPS | MEDTRONIC, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157373-A1 | ANTIMICROBIAL COMPOUNDS HAVING PROTECTIVE OR THERAPEUTIC LEAVING GROUPS | LTN1, VIP, CTSA | LMNA 1167/4885ALDH1A1 593/4885CYP3A4 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.